What are the latest funding news in the longevity market? (September 2026)
Download our beautiful pitch about the longevity market
In our longevity market deck, you will find everything you need to understand the market
The 12 publicly announced longevity market funding rounds covered here were announced between March 13, 2026 and August 10, 2026.
They include companies building longevity therapeutics, biological-age diagnostics, preventive-health platforms, professional skincare products, and longevity clinics.
And if you want to better understand this new industry, you can download our pitch covering the longevity market.
Insights
- NewLimit alone represented nearly 71% of the $613.9 million in disclosed longevity market funding, showing how strongly investors are concentrating capital behind cellular rejuvenation platforms nearing clinical translation.
- Eight of the 12 rounds backed therapeutic or regenerative-medicine companies, confirming that longevity biotech remained the dominant funding category despite growing interest in consumer healthspan services.
- Cellular reprogramming was the highest-conviction scientific theme, with NewLimit, Retro Biosciences, and Life Biosciences all developing approaches intended to restore more youthful cell function.
- Five seed or pre-seed rounds show that investors continued to finance early longevity science, especially in exosomes, blood-stem-cell rejuvenation, inflammaging, and proteomic measurement.
- Preventive longevity care was also active: Lucis, Entourage AI, and TMRW raised capital for biomarker testing, biological-age measurement, and clinician-guided health optimization.
- Two companies disclosed multibillion-dollar valuation benchmarks: NewLimit at approximately $3.1 billion and Retro Biosciences at a $1.8 billion pre-money valuation.
- The United States led the deal flow, but France, the United Kingdom, Singapore, and Australia all contributed meaningful longevity market fundraising activity during the period.
As this slide shows, and as featured in our longevity market deck, online search interest in longevity has been steadily increasing
Summary table of the latest funding deals in the longevity market as of September 2026
We define the longevity market as products and services that use science, medicine, or technology to extend healthy years of life and slow or improve the effects of aging.
We include therapies, diagnostics, clinics, digital tools, supplements, and programs that are explicitly designed and marketed to improve healthspan, prevent age-related decline, or optimize long-term health.
We exclude generic healthcare, wellness, beauty, fitness, eldercare, and financial products that serve older adults but are not specifically focused on longevity or healthspan.
You can also read our detailed analysis to understand how funding activity in the longevity market has evolved over the last few years.
We also have a quarter-by-quarter analysis of funding activity in the market here.
Finally, you can check our complete list of fundraising deals for the longevity market (we update this list every quarter) as well as our ranking of the most funded startups.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| Remedium Bio | August 10, 2026 | $10M | Series A initial close | Longevity Therapeutics & Regenerative Gene Therapy |
| Rapalogix Health | June 23, 2026 | $20M | Series A | Longevity Dermatology & Skin Health |
| Gero | June 17, 2026 | $17M | Equity financing | AI Geroscience & Drug Discovery |
| Human Continuum | June 11, 2026 | $5.13M | Seed | Exosome Therapeutics & Diagnostics |
| NewLimit | June 2, 2026 | $435M | Series C | Cellular Rejuvenation & Epigenetic Reprogramming |
| Lucis | May 26, 2026 | $20M | Series A | Preventive Health & Longevity Diagnostics |
| Retro Biosciences | May 22, 2026 | Undisclosed | New financing round | Cellular Rejuvenation & Age-Related Disease Therapeutics |
| Life Biosciences | April 8, 2026 | $80M | Series D | Epigenetic Reprogramming & Longevity Therapeutics |
| HexemBio | April 7, 2026 | $10.4M | Seed | Stem-Cell Rejuvenation & Regenerative Medicine |
| Entourage AI | March 18, 2026 | $5M | Pre-seed | Biological-Age Diagnostics & Proteomics |
| Ternary Therapeutics | March 16, 2026 | Approximately $4.4M | Seed | Inflammaging Therapeutics & AI Drug Discovery |
| TMRW | March 13, 2026 | Approximately $7M | Seed | Longevity Clinics & Preventive Medicine |
All the latest funding deals during in the longevity market as of September 2026
Remedium Bio raised an initial $10 million Series A close in August 2026.
When was it?
Remedium Bio announced the initial close of its Series A financing on August 10, 2026.
Who are they?
Remedium Bio develops adjustable injectable gene therapies that make a patient’s own fat cells produce therapeutic proteins over time.
Geographical focus?
Remedium Bio is based in Boston and is focused initially on United States clinical development.
Why do we include them in the longevity market?
Remedium Bio belongs in the longevity market because its regenerative gene therapies target chronic diseases and diseases of aging.
What is the company stage?
Remedium Bio is preclinical and preparing its lead programs for first-in-human studies.
How much did they raise?
Remedium Bio raised an initial $10 million for this financing round.
What round is it?
Remedium Bio described the financing as an initial close of a Series A round.
Why did they raise?
Remedium Bio raised the capital to expand its Prometheus platform, advance therapeutic programs, and prepare for human trials.
Rapalogix Health raised $20 million in a Series A round in June 2026.
When was it?
Rapalogix Health announced its Series A financing on June 23, 2026.
Who are they?
Rapalogix Health develops professional skincare products and dermatology therapies that target biological mechanisms associated with skin aging.
Geographical focus?
Rapalogix Health is based in California and is expanding its professional skincare business across the United States.
Why do we include them in the longevity market?
Rapalogix Health belongs in the longevity market because its products are built around cellular longevity science and healthier skin aging.
What is the company stage?
Rapalogix Health is in commercial growth, with its Re-Q professional skincare line already entering the market.
How much did they raise?
Rapalogix Health raised $20 million in the Series A round.
What round is it?
Rapalogix Health raised a Series A round co-led by Woodline Partners and GordonMD Global Investments.
Why did they raise?
Rapalogix Health raised the capital to expand Re-Q commercially and develop more products for skin longevity and age-related skin changes.
This chart, featured in our longevity market deck, compares the main business model options for longevity clinics
Gero raised $17 million in new equity financing in June 2026.
When was it?
Gero announced the new financing on June 17, 2026.
Who are they?
Gero uses AI, physics-based models, and longitudinal health data to discover medicines for aging and age-related disease.
Geographical focus?
Gero operates across Singapore and San Francisco while building a globally relevant drug-discovery platform.
Why do we include them in the longevity market?
Gero belongs in the longevity market because its core mission is to develop medicines that target aging biology and extend healthy lifespan.
What is the company stage?
Gero is in discovery and preclinical development, with pharmaceutical collaborations supporting its platform.
How much did they raise?
Gero raised $17 million in new equity financing, bringing reported equity funding to approximately $34 million.
What round is it?
Gero described the transaction as new equity financing, although some market databases classify it as a Series B.
Why did they raise?
Gero raised the capital to grow its AI platform, improve models of biological aging, and advance drug programs for chronic age-related diseases.
Human Continuum raised $5.13 million in seed funding in June 2026.
When was it?
Human Continuum announced its seed financing on June 11, 2026.
Who are they?
Human Continuum develops platelet-derived and plant-based exosome therapies, diagnostics, and biomarker tools for tissue repair and long-term health.
Geographical focus?
Human Continuum is based in Jupiter, Florida and is focused initially on United States research and clinical development.
Why do we include them in the longevity market?
Human Continuum belongs in the longevity market because its exosome platform targets systemic rejuvenation, inflammation reduction, and regenerative medicine.
What is the company stage?
Human Continuum is a seed-stage company with preclinical therapeutic and diagnostic programs.
How much did they raise?
Human Continuum raised $5.13 million in seed financing.
What round is it?
Human Continuum raised a seed round funded by existing shareholders.
Why did they raise?
Human Continuum raised the capital to hire technical talent, strengthen research and development, and accelerate its integrated exosome platform.
This chart, featured in our longevity market deck, looks at Function Health’s strategy in longevity
NewLimit raised $435 million in a Series C round in June 2026.
When was it?
NewLimit announced its Series C financing on June 2, 2026.
Who are they?
NewLimit develops medicines that use partial cellular reprogramming to restore more youthful function in old cells.
Geographical focus?
NewLimit is based in the San Francisco Bay Area and is building its therapeutic platform for human clinical development.
Why do we include them in the longevity market?
NewLimit belongs in the longevity market because its core purpose is to create medicines that reverse aspects of cellular aging and extend healthspan.
What is the company stage?
NewLimit is late preclinical and clinical-enabling, with its first human study expected to begin in 2027.
How much did they raise?
NewLimit raised $435 million in the financing round.
What round is it?
NewLimit raised a Series C led by Founders Fund at an approximately $3.1 billion valuation.
Why did they raise?
NewLimit raised the capital to move its first reprogramming medicine toward clinical trials, expand manufacturing, and build additional aging programs.
Lucis raised $20 million in a Series A round in May 2026.
When was it?
Lucis announced its Series A financing on May 26, 2026.
Who are they?
Lucis combines blood biomarker testing, clinician input, and AI guidance to help people identify and manage health risks earlier.
Geographical focus?
Lucis started in France and is expanding its preventive-health service across European markets.
Why do we include them in the longevity market?
Lucis belongs in the longevity market because its platform uses biomarkers and personalized prevention to support long-term healthspan optimization.
What is the company stage?
Lucis is in early commercial growth, with more than 10,000 users reported by the company.
How much did they raise?
Lucis raised $20 million in the Series A round.
What round is it?
Lucis raised a Series A led by Singular, with General Catalyst and Y Combinator participating.
Why did they raise?
Lucis raised the capital to enter more European markets and further develop its AI-driven preventive-health companion.
In our longevity market deck, we identify pain points entrepreneurs should prioritize
Retro Biosciences announced an undisclosed new financing round in May 2026.
When was it?
Retro Biosciences announced the initial close of its financing round on May 22, 2026.
Who are they?
Retro Biosciences develops therapies based on cellular reprogramming, cell replacement, and other approaches to restore youthful tissue function.
Geographical focus?
Retro Biosciences is based in San Francisco and is pursuing clinical development in the United States.
Why do we include them in the longevity market?
Retro Biosciences belongs in the longevity market because its stated mission is to add healthy years to human life by addressing biological aging.
What is the company stage?
Retro Biosciences is clinical stage, with an Alzheimer’s-related therapeutic study underway and other rejuvenation programs in development.
How much did they raise?
Retro Biosciences did not disclose the amount raised in this financing round.
What round is it?
Retro Biosciences described the transaction as a new financing round, while some databases classify it as a Series A extension.
Why did they raise?
Retro Biosciences raised the capital to support clinical development and expand its cellular reprogramming, cell therapy, and protein-engineering programs.
Life Biosciences raised $80 million in a Series D round in April 2026.
When was it?
Life Biosciences announced its Series D financing on April 8, 2026.
Who are they?
Life Biosciences develops partial epigenetic-reprogramming gene therapies designed to restore youthful cell function in age-related diseases.
Geographical focus?
Life Biosciences is headquartered in Boston and is developing clinical programs in the United States.
Why do we include them in the longevity market?
Life Biosciences belongs in the longevity market because its entire platform is focused on cellular rejuvenation and diseases driven by aging.
What is the company stage?
Life Biosciences is clinical stage, with ER-100 in a Phase 1 study for optic neuropathies.
How much did they raise?
Life Biosciences raised $80 million in the Series D financing.
What round is it?
Life Biosciences raised a fully subscribed Series D round, although the investors were not publicly disclosed.
Why did they raise?
Life Biosciences raised the capital to fund its Phase 1 ER-100 trial and advance more candidates from its reprogramming platform.
This market map, featured in our longevity market deck, highlights top companies and startups in the longevity market
HexemBio raised $10.4 million in seed funding in April 2026.
When was it?
HexemBio announced its seed financing on April 7, 2026.
Who are they?
HexemBio rejuvenates a patient’s aging blood stem cells outside the body before returning them through an intravenous infusion.
Geographical focus?
HexemBio is focused on United States clinical development and has roots in the Pittsburgh biotechnology ecosystem.
Why do we include them in the longevity market?
HexemBio belongs in the longevity market because its platform aims to restore more youthful blood stem-cell and immune-system function.
What is the company stage?
HexemBio is preclinical and completing IND-enabling work ahead of a planned first-in-human study.
How much did they raise?
HexemBio raised $10.4 million in seed funding.
What round is it?
HexemBio raised a seed round led by Draper Associates, with participation from SOSV, Seraphim Space, and Treeo VC.
Why did they raise?
HexemBio raised the capital for regulatory preparation, manufacturing work, and progression toward its first clinical study.
Entourage AI raised $5 million in a pre-seed round in March 2026.
When was it?
Entourage AI announced the pre-seed financing on March 18, 2026.
Who are they?
Entourage AI analyzes thousands of proteins in blood to measure biological age, assess organ health, and identify earlier health risks.
Geographical focus?
Entourage AI is based in Glasgow and is targeting customers and partners in the United Kingdom and United States.
Why do we include them in the longevity market?
Entourage AI belongs in the longevity market because its core products measure biological aging and support earlier, more personalized intervention.
What is the company stage?
Entourage AI is at the pre-launch and early commercial stage, with its products available for preorder.
How much did they raise?
Entourage AI raised $5 million in pre-seed funding.
What round is it?
Entourage AI raised a pre-seed round led by Provision, with GU Holdings, David Peterson, Brad Peltz, and angel investors participating.
Why did they raise?
Entourage AI raised the capital to build its Glasgow research center, expand proteomics infrastructure, and prepare its commercial launch.
This chart, featured in our longevity market deck, illustrates yearly funding for longevity startups
Ternary Therapeutics raised approximately $4.4 million in seed funding in March 2026.
When was it?
Ternary Therapeutics announced its seed round on March 16, 2026.
Who are they?
Ternary Therapeutics uses physics-informed AI and laboratory testing to discover molecular-glue medicines for age-related disease.
Geographical focus?
Ternary Therapeutics is based in London and operates a globally oriented drug-discovery model.
Why do we include them in the longevity market?
Ternary Therapeutics belongs in the longevity market because its lead scientific focus is inflammaging, a chronic inflammatory process linked to aging.
What is the company stage?
Ternary Therapeutics is a preclinical discovery company that is still validating its molecular-glue platform.
How much did they raise?
Ternary Therapeutics raised approximately $4.4 million, equivalent to £3.6 million at announcement.
What round is it?
Ternary Therapeutics raised a seed round led by daphni, with Pace Ventures, i&i Biotech Fund, and Future Planet Capital participating.
Why did they raise?
Ternary Therapeutics raised the capital to scale its AI platform, run experimental validation faster, and create a repeatable drug-discovery process.
TMRW raised approximately $7 million in seed funding in March 2026.
When was it?
TMRW announced its seed financing on March 13, 2026.
Who are they?
TMRW operates a preventive-health membership that combines biological-age testing, clinician review, diagnostics, and personalized health plans.
Geographical focus?
TMRW is focused initially on Australia, where it is expanding its clinical footprint and care-delivery model.
Why do we include them in the longevity market?
TMRW belongs in the longevity market because its service is explicitly built around longevity medicine, biological-age testing, and proactive healthspan care.
What is the company stage?
TMRW is in early commercial growth as it expands from a digital service into physical longevity-care locations.
How much did they raise?
TMRW raised approximately $7 million in seed funding.
What round is it?
TMRW raised a seed round led by Tidal Ventures, with Capital Zed, family offices, entrepreneurs, and existing members participating.
Why did they raise?
TMRW raised the capital to expand clinics, improve its patient experience, and deepen biological-age testing capabilities.
